secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001193125-22-221242
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Q2 net loss $10.2M; cash $209.9M; Phase 1 topline H1 2023; director resigns
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $209.9M as of June 30, 2022; expected runway through 2025.
- Net loss $10.2M for Q2 2022 vs $61.4M in Q2 2021 (2021 incl $57.9M non-cash liability charge).
- R&D expenses $7.3M (up from $2.3M) due to ongoing Phase 1 INTERCEPT-AD trial.
- Phase 1 INTERCEPT-AD topline results expected H1 2023; 15 active sites recruiting.
- Dr. Jeffrey Sevigny resigned from Board effective Aug 12, 2022 due to employment requirements, not disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522221242/0001193125-22-221242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522221242/d254943d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-221242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer